Tocagen (NASDAQ:TOCA) – Stock analysts at B. Riley issued their Q2 2018 earnings estimates for shares of Tocagen in a research note issued to investors on Wednesday, May 16th. B. Riley analyst M. Kumar expects that the company will earn ($0.63) per share for the quarter. B. Riley currently has a “Buy” rating and a $15.00 target price on the stock. B. Riley also issued estimates for Tocagen’s Q3 2018 earnings at $0.17 EPS, Q4 2018 earnings at ($0.43) EPS, FY2018 earnings at ($1.56) EPS, Q1 2019 earnings at ($0.74) EPS, Q2 2019 earnings at ($0.71) EPS, Q3 2019 earnings at ($0.68) EPS, Q4 2019 earnings at ($0.65) EPS and FY2019 earnings at ($2.61) EPS.
Tocagen (NASDAQ:TOCA) last announced its quarterly earnings results on Thursday, May 10th. The company reported ($0.65) EPS for the quarter. Tocagen had a negative return on equity of 57.09% and a negative net margin of 109,579.49%. The company had revenue of $0.01 million during the quarter.
Shares of TOCA stock opened at $9.90 on Friday. Tocagen has a 52 week low of $9.57 and a 52 week high of $9.76. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.56 and a quick ratio of 5.23.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. grew its position in Tocagen by 36.4% during the fourth quarter. BlackRock Inc. now owns 1,069,152 shares of the company’s stock valued at $10,960,000 after buying an additional 285,396 shares during the period. Lake Street Advisors Group LLC bought a new stake in Tocagen during the fourth quarter valued at approximately $1,042,000. Artal Group S.A. bought a new stake in Tocagen during the fourth quarter valued at approximately $1,025,000. Geode Capital Management LLC grew its position in Tocagen by 16.0% during the fourth quarter. Geode Capital Management LLC now owns 90,452 shares of the company’s stock valued at $927,000 after buying an additional 12,472 shares during the period. Finally, Russell Investments Group Ltd. grew its position in Tocagen by 107.4% during the first quarter. Russell Investments Group Ltd. now owns 81,067 shares of the company’s stock valued at $961,000 after buying an additional 41,978 shares during the period. Institutional investors own 32.48% of the company’s stock.
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.